Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys

mAbs

Volumn 4, Issue 2, 2012, Pages 267-273

  Datta Mannan, Amita ^a   Witcher, Derrick R ^a   Lu, Jirong ^a   Wroblewski, Victor J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody bioavailability; Antibody pharmacokinetics; Antibody pharmacokinetics in monkey; Fc engineering; FcRn

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYNOMORIACEAE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; MALE; MAXIMUM PLASMA CONCENTRATION; MUTATION; NONHUMAN; RECEPTOR BINDING; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; BIOAVAILABILITY; CELL LINE; GENETICS; HALF LIFE TIME; HUMAN; IMMUNOLOGY; MACACA FASCICULARIS; MISSENSE MUTATION; MOUSE; SUBCUTANEOUS DRUG ADMINISTRATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL AVAILABILITY; CELL LINE; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFUSIONS, SUBCUTANEOUS; MACACA FASCICULARIS; MICE; MUTATION, MISSENSE; RECEPTORS, FC; RECOMBINANT PROTEINS;

EID: 84863275336     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.2.19364     Document Type: Article

References (21)

1. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460-70; PMID:18656541; http://dx.doi.org/10.1016/j. coi.2008.06.012.
2. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155.
3. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15:637-40; PMID:9219265; http://dx.doi.org/10.1038/nbt0797-637.
4. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 2004; 101:11076-81; PMID:15258288; http://dx.doi.org/10.1073/ pnas.0402970101.
5. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 2004; 172:2021-9; PMID:14764666.
6. Prabhat P, Gan Z, Chao J, Ram S, Vaccaro C, Gibbons S, et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci USA 2007; 104:5889-94; PMID:17384151; http://dx.doi.org/10.1073/pnas.0700337104.
7. Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, Dunn KW. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 2008; 19:5490-505; PMID:18843053; http://dx.doi.org/10.1091/mbc.E07-02-0101.
8. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80; PMID:12391234.
9. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282:1709-17; PMID:17135257; http://dx.doi.org/10.1074/jbc.M607161200.
10. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:86-94; PMID:17050651; http://dx.doi.org/10.1124/dmd.106.011734.
11. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279:6213-6; PMID:14699147; http://dx.doi.org/10.1074/jbc.C300470200.
12. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346-56; PMID:16365427.
13. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182.
14. Yeung YA, Wu X, Reyes AE, 2nd, Vernes JM, Lien S, Lowe J, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010; 70:3269-77; PMID:20354184; http://dx.doi.org/10.1158/0008-5472.CAN-09-4580.
15. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58; PMID:18784655; http://dx.doi.org/10.1038/clpt.2008.170.
16. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID:20071453; http://dx.doi.org/10.1124/dmd. 109.031310.
17. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci USA 2006; 103:18709-14; PMID:17116867; http://dx.doi.org/10.1073/pnas.0606304103.
18. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15:637-40; PMID:9219265; http://dx.doi.org/10.1038/nbt0797-637.
19. Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29:490-9; PMID:21887597; http://dx.doi.org/10.1007/s11095-011-0578-3.
20. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283-8; PMID:16186811; http://dx.doi.org/10.1038/nbt1143.
21. Kunkel TA, Roberts JD, Zakour RA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 1987; 154:367-82; PMID:3323813; http://dx.doi.org/10.1016/0076-6879(87)54085-X.